PT-141 and Viagra Are Not Alternatives: Different Mechanism, Different Approved Population

Every result on the first page for this question treats PT-141 and Viagra as two options for the same problem, and picks a winner.

Look at the two labels and the comparison collapses. One is approved for premenopausal women with a desire disorder. The other is approved for men with erectile dysfunction, and states in three separate places that it is not for use in women.

They are not alternatives. Understanding why is more useful than a verdict nobody's evidence supports.

The Short Answer

The two drugs are approved for different conditions in different populations, and act through entirely different mechanisms.

PT-141 is the development name commonly used for bremelanotide. Vyleesi® is the FDA-approved product — a 1.75 mg subcutaneous bremelanotide injection, and a melanocortin receptor agonist approved for acquired, generalized hypoactive sexual desire disorder in premenopausal women. Its label states it is not indicated for men.

Sildenafil — sold as VIAGRA — is a PDE5 inhibitor approved for erectile dysfunction. Its label states it is not indicated for use in females.

One more distinction the comparison depends on: compounded preparations containing bremelanotide or "PT-141" are not Vyleesi and are not FDA-approved drug products. Everything compared below is the approved product against the approved product. A compounded preparation has no approved indication, no label and no trial data of its own, so Vyleesi's trial results and label instructions should not be transferred to it.

There is no head-to-head trial comparing FDA-approved Vyleesi treatment for female HSDD with Viagra treatment for male ED, and the approved populations do not overlap.

And they measure different things: one was tested against desire and distress questionnaires, the other against the ability to achieve and maintain an erection.

What Each Label Says It Treats

VIAGRA

The indication is a single sentence: "VIAGRA is indicated for the treatment of erectile dysfunction."

The label's position on women is not silence — it is explicit, and repeated. Section 8.1 states: "VIAGRA is not indicated for use in females." Section 8.2 repeats it. The patient counselling section says: "VIAGRA is not for use in women or children. It is not known if VIAGRA is safe and effective in women or children under 18 years of age."

The clinical studies section describes what was tested: the effect "on the ability of men with erectile dysfunction to engage in sexual activity."

Read the current VIAGRA prescribing information on DailyMed.

VYLEESI

The indication is considerably longer, and every clause narrows it: "premenopausal women with acquired, generalized hypoactive sexual desire disorder (HSDD), as characterized by low sexual desire that causes marked distress or interpersonal difficulty and is NOT due to: A co-existing medical or psychiatric condition, Problems with the relationship, or The effects of a medication or drug substance."

Its Limitations of Use are equally direct: "VYLEESI is not indicated for the treatment of HSDD in postmenopausal women or in men. VYLEESI is not indicated to enhance sexual performance."

Read the current VYLEESI prescribing information on DailyMed.

Different Mechanisms Entirely

This is where the comparison is most often described wrongly, usually as "one works on the brain and the other on blood flow." That is roughly the right shape, but the labels are more precise — and more honest about what is unknown.

Sildenafil: a well-characterised mechanism

The VIAGRA label explains it in full, and the last sentence is the one that matters most:

"The physiologic mechanism of erection of the penis involves release of nitric oxide (NO) in the corpus cavernosum during sexual stimulation… Sildenafil enhances the effect of NO by inhibiting phosphodiesterase type 5 (PDE5), which is responsible for degradation of cGMP in the corpus cavernosum. Sildenafil has no direct relaxant effect on isolated human corpus cavernosum… Sildenafil at recommended doses has no effect in the absence of sexual stimulation."

In other words, sildenafil does not create sexual desire. It enhances the erectile-response pathway when sexual stimulation is present. So if low desire is the primary problem, sildenafil does not directly treat that underlying problem.

Note what the label is and is not saying. It requires sexual stimulation — not that the person's desire is normal. Those are different things, and a drug that acts on erectile physiology during stimulation is not thereby a treatment for a desire disorder.

Bremelanotide: an unknown one

The VYLEESI label describes bremelanotide as a melanocortin receptor agonist that "nonselectively activates several receptor subtypes," with MC1R and MC4R binding "most relevant" at therapeutic doses. MC4R receptors are widely distributed in the central nervous system.

But the same section states: "The mechanism by which VYLEESI improves HSDD in women is unknown."

So the honest version of the contrast is this. Sildenafil's mechanism is characterised in detail and depends on sexual stimulation being present. Bremelanotide's mechanism of clinical benefit in HSDD is not established, and the label says so. One acts on a well-mapped physiological pathway; the other is an approved drug whose route to its effect remains a research question.

They Were Measured Against Different Things

Even setting aside the population difference, the trials do not produce comparable numbers.

Vyleesi's phase 3 trials — 1,267 women, 24 weeks — had two co-primary endpoints, both questionnaires: a desire domain score and a distress item. It improved both by small margins. The trials did not show a statistically significant increase in the number of satisfying sexual events, a pre-specified secondary endpoint, in either trial (p = 0.76 and p = 0.70).

Sildenafil's trials assessed the ability of men with erectile dysfunction to achieve and maintain an erection sufficient for satisfactory sexual activity.

Desire and erectile response are not the same outcome, and no scale converts one into the other. A "which works better" comparison would require a common measure in a common population, and neither exists.

The Same Molecule Is Approved in a Population That Includes Women — For Something Else

One nuance is worth getting right, because it is frequently stated as a flat "sildenafil was never approved for women," and that is not quite true.

Sildenafil is FDA-approved under a different brand, for a different disease, in a population that includes women. REVATIO is sildenafil approved "for the treatment of pulmonary arterial hypertension… in adults to improve exercise ability and delay clinical worsening." The indication is written for adults, with no sex restriction.

Women were heavily represented in its pivotal trials: the label reports one adult study population as "25% men and 75% women," and another as "80% were female."

So the accurate statement is narrower and more interesting. Sildenafil is FDA-approved for pulmonary arterial hypertension in adults under the brand Revatio, and women made up most of the pivotal trial populations. That does not create a female sexual-health indication. Whether sildenafil does anything for female sexual function is a separate question with its own literature: Can Women Take Viagra? What Sildenafil Does and Doesn't Do.

What About PT-141 for Men?

This is the assumption underneath most versions of this search, and the evidence does not support it.

Bremelanotide has never been approved for men, in any indication. The VYLEESI label excludes them by name.

There is an early male research programme, and it is worth knowing exactly what it consists of.

Two 2004 studies by researchers affiliated with the developer. One tested intranasal PT-141; the other tested subcutaneous PT-141 in healthy men and in men reporting an inadequate response to Viagra. Both measured erectile response by RigiScan — a device-based surrogate, not real-world sexual outcomes.

A 2005 crossover study of 19 men that combined low-dose intranasal PT-141 with low-dose sildenafil, again using RigiScan during visual sexual stimulation.

A 2008 trial of 342 married men who had not responded to sildenafil. Unlike the earlier work, this one used real-world outcomes — home attempts assessed with the International Index of Erectile Function and an intercourse-satisfaction domain — and it reported a positive result.

That last trial is the one the male case largely rests on, and its status needs stating carefully. It has carried a formal Expression of Concern from the Journal of Urology since January 2023. An Expression of Concern is not a retraction and is not a finding that the results are wrong; it is a notice that unresolved concerns exist.

But it does not stand alone. A separate bremelanotide study by the same author — a trial in women with arousal disorder, published in the Journal of Sexual Medicine in 2008 — has been fully retracted. That journal's retraction notice states that it re-reviewed the author's papers following retractions of his work by other journals, that its reviewers "raised multiple concerning questions about the methodology, results, and statistical interpretation," and that the author did not respond to requests for his original data, so it could "no longer verify the results or methods as presented."

Taken together: the largest male efficacy trial carries an unresolved Expression of Concern, and the same author's companion bremelanotide paper was retracted after a journal could not verify his methods or results. Its efficacy and dosing findings should be treated with considerable caution, which is why we do not report them here.

The intranasal male programme was discontinued. The later successful regulatory programme focused on subcutaneous bremelanotide for premenopausal women with HSDD, which is the product that reached approval. As recently as 2026, a commentary in a psychopharmacology journal was still asking whether bremelanotide should be considered for men. Our reading of that is interpretation rather than fact: a 2026 expert commentary still debating the question suggests the male use remains an investigational question rather than an established one.

The male dosing figures circulating online trace back to the trial now carrying that Expression of Concern. There is no validated male dosing, and this article does not supply one.

So What Is the Actual Question?

Most people searching this comparison are not choosing between two products. They are trying to work out which problem they have.

The distinction the two labels draw is the useful one. Desire, subjective arousal and erectile response are related but distinct aspects of sexual function. They do not run in a fixed sequence — genital response can occur without much conscious desire, and desire can emerge in response to stimulation rather than preceding it. What follows from that is narrower than "one treats desire, one treats arousal": a medication aimed at erectile physiology should not be assumed to treat a disorder of sexual desire, and vice versa.

Which of those is actually happening, and why, is a clinical assessment. It has causes ranging from medications and hormonal conditions to sleep, mood, pain and circumstance, and no article can sort them for an individual. Related reading: PT-141 vs. Sildenafil vs. Tadalafil: What's the Difference? and What PT-141 Actually Is, Who It Is Approved For, and What the Trials Found.

Frequently Asked Questions

Is PT-141 better than Viagra?

The question has no evidence-based answer, because the two are approved for different conditions in different populations and no head-to-head trial exists. PT-141 is approved for premenopausal women with a desire disorder; Viagra for men with erectile dysfunction. They were also measured against different endpoints — questionnaires about desire and distress in one case, erectile response in the other.

What is the difference between PT-141 and Viagra?

Mechanism, indication and population. Sildenafil inhibits PDE5 and enhances the erectile-response pathway when sexual stimulation is present — its label states it "has no effect in the absence of sexual stimulation." Bremelanotide activates melanocortin receptors, and its label states the mechanism by which it improves HSDD "is unknown." One is approved for men, the other for premenopausal women.

Can men take PT-141?

There is no FDA-approved bremelanotide indication for men. Bremelanotide has been studied experimentally in men, but the current Vyleesi label specifically excludes them: it "is not indicated for the treatment of HSDD in postmenopausal women or in men." That male research consists of two 2004 developer-affiliated studies using device-based surrogate measures, a 19-man crossover from 2005, and one 342-man trial that has carried a formal Expression of Concern from the Journal of Urology since January 2023 — and whose author had a companion bremelanotide paper retracted by another journal. Whether any treatment is appropriate for an individual is a decision for a prescribing clinician.

Can women take Viagra?

Viagra is not FDA-approved for female sexual dysfunction. Sildenafil has been studied in women and can be prescribed off-label in some circumstances, but the Viagra label itself is for erectile dysfunction and states that Viagra is "not indicated for use in females." Separately, sildenafil is FDA-approved for adults with pulmonary arterial hypertension under the brand Revatio, where women made up 75–80% of the pivotal trial populations — a lung and vascular indication, not a sexual one.

Does PT-141 work like Viagra?

No. Sildenafil acts on the erectile blood-flow pathway, and its label states it has no effect in the absence of sexual stimulation — it does not treat low desire. Bremelanotide binds melanocortin receptors, and the label states the mechanism of its effect in HSDD is unknown. The common description of PT-141 as acting "on the brain" is an inference from where MC4R receptors are found, not a demonstrated human mechanism.

Can you take PT-141 and Viagra together?

A small 2005 randomised crossover study in 19 men tested low-dose intranasal PT-141 with low-dose sildenafil and found a greater device-measured erectile response than sildenafil alone. That study was small, used an older intranasal formulation that was never approved, measured a surrogate rather than real-world outcomes, and involved a population for which bremelanotide is not FDA-approved. It does not establish a current combination-treatment protocol, and this article does not describe one. Combining prescription medications is a decision for a prescribing clinician.

Which one is for low libido?

Of the two, only bremelanotide is approved for a desire disorder, and only in premenopausal women meeting a narrow definition. Sildenafil is not FDA-approved to treat low sexual desire; its established sexual-health indication is erectile dysfunction, and its mechanism supports erectile response during sexual stimulation rather than treating HSDD.

Is PT-141 the same as Vyleesi?

Not exactly. PT-141 is the development name for the drug substance bremelanotide; Vyleesi® is the FDA-approved 1.75 mg subcutaneous bremelanotide product, with an approved label and indication. Compounded preparations containing bremelanotide or "PT-141" are not Vyleesi and are not FDA-approved drug products. Every label quotation and trial result on this page comes from Vyleesi. Fuller detail: What PT-141 Actually Is, Who It Is Approved For, and What the Trials Found.

AmalfiDuo Sexual Wellness Programs

If you're exploring ways to support your sexual wellness, AmalfiDuo offers private, provider-guided care programs for adults. A licensed clinician reviews your health information to determine whether treatment is appropriate.

Explore Sexual Wellness Programs

A prescription is never guaranteed.

References

1. VYLEESI (bremelanotide) injection — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Sections 1, 2.1 and 12.1.
2. VIAGRA (sildenafil citrate) tablets — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Sections 1, 2.1, 8.1, 8.2, 12.1, 14 and 17.
3. REVATIO (sildenafil) — U.S. Prescribing Information. DailyMed, U.S. National Library of Medicine. Sections 1 and 14.
4. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019;134(5):899–908. PMID 31599840.
5. Diamond LE, Earle DC, Rosen RC, Willett MS, Molinoff PB. Double-blind, placebo-controlled evaluation of the safety, pharmacokinetic properties and pharmacodynamic effects of intranasal PT-141. International Journal of Impotence Research. 2004;16(1):51–59. PMID 14963471.
6. Rosen RC, Diamond LE, Earle DC, Shadiack AM, Molinoff PB. Evaluation of the safety, pharmacokinetics and pharmacodynamic effects of subcutaneously administered PT-141 in healthy male subjects and in patients with an inadequate response to Viagra. International Journal of Impotence Research. 2004;16(2):135–142. PMID 14999221.
7. Diamond LE, Earle DC, Garcia WD, Spana C. Co-administration of low doses of intranasal PT-141, a melanocortin receptor agonist, and sildenafil to men with erectile dysfunction results in an enhanced erectile response. Urology. 2005;65(4):755–759. PMID 15833522.
8. Safarinejad MR, Hosseini SY. Salvage of sildenafil failures with bremelanotide: a randomized, double-blind, placebo controlled study. Journal of Urology. 2008;179(3):1066–1071. PMID 18206919. Subject to an Expression of Concern: J Urol, 10 January 2023, PMID 36626345.
9. RETRACTED — Safarinejad MR. Evaluation of the safety and efficacy of bremelanotide in female subjects with arousal disorder. Journal of Sexual Medicine. 2008;5(4):887–897. PMID 18179455. Retracted by the journal; cited here only as the record of that retraction.
10. Pfaus JG, Balon R. Should Bremelanotide Be Considered for the Treatment of Sexual Arousal and Desire Disorders in Men? Journal of Clinical Psychopharmacology. 2026;46(3):245–248. PMID 41960633.

This article is provided for general educational purposes only and is not a substitute for individualized medical advice, diagnosis or treatment. It reports the contents of FDA-approved prescribing information and published research, and does not recommend any treatment, dose or combination. The bremelanotide information here describes Vyleesi®, the FDA-approved product, and does not describe compounded preparations. Sexual difficulties have many possible causes and require clinical assessment. Questions about whether a treatment is appropriate should be discussed with a qualified healthcare professional. AmalfiDuo Journal articles are written by AmalfiDuo Editorial and are not medically reviewed — see our Editorial Policy.

VYLEESI®, VIAGRA® and REVATIO® are trademarks of their respective owners. AmalfiDuo is not affiliated with or endorsed by the owners or manufacturers of these brands.